PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence

被引：16

作者：

Bienkowski, Michal ^{[1
]}

Tomasik, Bartlomiej ^{[2
]}

Braun, Marcin ^{[3
]}

Jassem, Jacek ^{[2
]}

机构：

[1] Med Univ Gdansk, Dept Pathomorphol, Smoluchowskiego 17, PL-80214 Gdansk, Poland

[2] Med Univ Gdansk, Dept Oncol & Radiotherapy, Smoluchowskiego 17, PL-80214 Gdansk, Poland

[3] Med Univ Lodz, Chair Oncol, Dept Pathol, Pomorska 251 St, PL-92213 Lodz, Poland

来源：

CANCER TREATMENT REVIEWS | 2022年 / 104卷

关键词：

Metastatic castration-resistant prostate cancer; Poly(ADP-ribose) polymerase; PARP inhibitors; Precision medicine; Predictive biomarkers; Synthetic lethality; HOMOLOGOUS RECOMBINATION DEFICIENCY; CELL-FREE DNA; 1ST-LINE THERAPY; REPAIR DEFECTS; GERMLINE BRCA1; PATIENTS PTS; MUTATIONS; OLAPARIB; BREAST; 53BP1;

D O I：

10.1016/j.ctrv.2022.102359

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose) polymerase inhibitors (PARPi) are the first clinically approved agents designed to exploit synthetic lethality. Based on the recent approvals, PARPi became available for patients with metastatic castration-resistant prostate cancer (mCRPC). Unlike breast or ovarian cancers, where the approvals are limited to patients with BRCA1/2 alterations, in mCRPC PARPi are offered to patients with a broader spectrum of aberrations. A growing body of data indicates that alterations in specific homologous recombination repair (HRR) genes may confer different sensitivities to PARPi. Another challenging issue is the optimal testing methodology for identifying these aberrations. This comprehensive review presents the current place of PARPi in the treatment of mCRPC, provide biological rationale explaining mechanisms of their action and resistance, and discuss current clinical challenges along with avenues for future research.

引用

页数：12

共 151 条

[1] Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration [J].

Abida, Wassim ;

Patnaik, Akash ;

Campbell, David ;

Shapiro, Jeremy ;

Bryce, Alan H. ;

McDermott, Ray ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Bambury, Richard M. ;

Voog, Eric ;

Zhang, Jingsong ;

Piulats, Josep M. ;

Ryan, Charles J. ;

Merseburger, Axel S. ;

Daugaard, Gedske ;

Heidenreich, Axel ;

Fizazi, Karim ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Sternberg, Cora N. ;

Watkins, Simon P. ;

Despain, Darrin ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Dowson, Melanie ;

Golsorkhi, Tony ;

Chowdhury, Simon .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) :3763-+

[2] Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study [J].

Abida, Wassim ;

Campbell, David ;

Patnaik, Akash ;

Shapiro, Jeremy D. ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Voog, Eric G. ;

Bryce, Alan H. ;

McDermott, Ray ;

Ricci, Francesco ;

Rowe, Julie ;

Zhang, Jingsong ;

Piulats, Josep Maria ;

Fizazi, Karim ;

Merseburger, Axel S. ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Ryan, Charles J. ;

Feng, Felix Y. ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Despain, Darrin ;

Dowson, Melanie ;

Green, Foad ;

Watkins, Simon P. ;

Golsorkhi, Tony ;

Chowdhury, Simon .

CLINICAL CANCER RESEARCH, 2020, 26 (11) :2487-2496

[3] Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making [J].

Abida, Wassim ;

Armenia, Joshua ;

Gopalan, Anuradha ;

Brennan, Ryan ;

Walsh, Michael ;

Barron, David ;

Danila, Daniel ;

Rathkopf, Dana ;

Morris, Michael ;

Slovin, Susan ;

McLaughlin, Brigit ;

Curtis, Kristen ;

Hyman, David M. ;

Durack, Jeremy C. ;

Solomon, Stephen B. ;

Arcila, Maria E. ;

Zehir, Ahmet ;

Syed, Aijazuddin ;

Gao, Jianjiong ;

Chakravarty, Debyani ;

Vargas, Hebert Alberto ;

Robson, Mark E. ;

Vijai, Joseph ;

Offit, Kenneth ;

Donoghue, Mark T. A. ;

Abeshouse, Adam A. ;

Kundra, Ritika ;

Heins, Zachary J. ;

Penson, Alexander V. ;

Harris, Christopher ;

Taylor, Barry S. ;

Ladanyi, Marc ;

Mandelker, Diana ;

Zhang, Liying ;

Reuter, Victor E. ;

Kantoff, Philip W. ;

Solit, David B. ;

Berger, Michael F. ;

Sawyers, Charles L. ;

Schultz, Nikolaus ;

Scher, Howard I. .

JCO PRECISION ONCOLOGY, 2017, 1 :1-26

[4] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[5]

Agency EM, 2015, PROV WITHDR MARK AUT

[6] Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study [J].

Aggarwal, Rahul ;

Huang, Jiaoti ;

Alumkal, Joshi J. ;

Zhang, Li ;

Feng, Felix Y. ;

Thomas, George V. ;

Weinstein, Alana S. ;

Friedl, Verena ;

Zhang, Can ;

Witte, Owen N. ;

Lloyd, Paul ;

Gleave, Martin ;

Evans, Christopher P. ;

Youngren, Jack ;

Beer, Tomasz M. ;

Rettig, Matthew ;

Wong, Christopher K. ;

True, Lawrence ;

Foye, Adam ;

Playdle, Denise ;

Ryan, Charles J. ;

Lara, Primo ;

Chi, Kim N. ;

Uzunangelov, Vlado ;

Sokolov, Artem ;

Newton, Yulia ;

Beltran, Himisha ;

Demichelis, Francesca ;

Rubin, Mark A. ;

Stuart, Joshua M. ;

Small, Eric J. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (24) :2492-+

[7] Detection of novel germline mutations for breast cancer in non-BRCA1/2 families [J].

Aloraifi, Fatima ;

McDevitt, Trudi ;

Martiniano, Rui ;

McGreevy, Jonah ;

McLaughlin, Russell ;

Egan, Chris M. ;

Cody, Nuala ;

Meany, Marie ;

Kenny, Elaine ;

Green, Andrew J. ;

Bradley, Daniel G. ;

Geraghty, James G. ;

Bracken, Adrian P. .

FEBS JOURNAL, 2015, 282 (17) :3424-3437

[8] When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials [J].

Antonarakis, Emmanuel S. ;

Gomella, Leonard G. ;

Petrylak, Daniel P. .

EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05) :594-611

[9] Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one? [J].

Antonarakis, Emmanuel S. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (08) :455-456

[10]

Antonarakis ES, 2020, JCO PRECIS ONCOL, V4, P370, DOI [10.1200/PO.19.00399, 10.1200/po.19.00399]

← 1 2 3 4 5 6 7 8 9 10 →